Journal article · 2020 · Open access
Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials
Journal of Scleroderma and Related Disorders, 5(2_suppl), 48–60 · Published 1 March 2020 · DOI 10.1177/2397198320904178
In brief
“Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials” is a 2020 journal article by Lesley Ann Saketkoo and 3 co-authors, published in Journal of Scleroderma and Related Disorders. OpenAlex counts 30 citations as of 22 November 2026. It is open access: the full text is free to read at Journal of Scleroderma and Related Disorders.
- Citations
- 30
- Most cited in
- 2022 (9)
- Field-weighted impact
- 2.16
- References
- 100
- Authors
- 4
Abstract
Systemic sclerosis (SSc) is a progressive vasculopathic, fibrosing autoimmune condition, portending significant mortality; wherein interstitial lung disease (ILD) is the leading cause of death. Although lacking a definitive cure, therapeutics for (SSc-ILD) that stave progression exist with further promising primary and adjuvant compounds in development, as well as interventions to reduce symptom burden and increase quality of life. To date, there has been a significant but varied history related to systemic sclerosis-related interstitial lung disease trial design and endpoint designation. This is especially true of endpoints measuring patient-reported perceptions of efficacy and tolerability. This article describes the underpinnings and complexity of the science, methodology, and current state of patient-reported outcome measures used in (SSc-ILD) systemic sclerosis-related interstitial lung disease in clinical practice and trials.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Saketkoo, L. A., Scholand, M. B., Lammi, M. R., & Russell, A. (2020). Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials. Journal of Scleroderma and Related Disorders, 5(2_suppl), 48–60. https://doi.org/10.1177/2397198320904178
MLA 9
Saketkoo, Lesley Ann, et al. “Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials.” Journal of Scleroderma and Related Disorders, vol. 5, no. 2_suppl, 2020, pp. 48–60. https://doi.org/10.1177/2397198320904178.
Chicago
Saketkoo, Lesley Ann, Mary Beth Scholand, Matthew R. Lammi, and Anne‐Marie Russell. 2020. “Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials.” Journal of Scleroderma and Related Disorders 5 (2_suppl): 48–60. https://doi.org/10.1177/2397198320904178.
Harvard
Saketkoo, L. A. et al. (2020) ‘Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials’, Journal of Scleroderma and Related Disorders, 5(2_suppl), pp. 48–60. doi:10.1177/2397198320904178.
IEEE
L. A. Saketkoo, M. B. Scholand, M. R. Lammi, and A. Russell, “Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials,” Journal of Scleroderma and Related Disorders, vol. 5, no. 2_suppl, pp. 48–60, 2020, doi: 10.1177/2397198320904178.
BibTeX
@article{saketkoo2020patient,
title = {{Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials}},
author = {Saketkoo, Lesley Ann and Scholand, Mary Beth and Lammi, Matthew R. and Russell, Anne‐Marie},
journal = {Journal of Scleroderma and Related Disorders},
year = {2020},
volume = {5},
number = {2_suppl},
pages = {48--60},
doi = {10.1177/2397198320904178},
url = {https://doi.org/10.1177/2397198320904178}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 1 | |
| 2020 | 1 | |
| 2021 | 3 | |
| 2022 | 9 | |
| 2023 | 2 | |
| 2024 | 5 | |
| 2025 | 5 | |
| 2026 | 4 |
Its field-weighted citation impact is 2.16: it has been cited 2.16 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- systemic sclerosis
- interstitial lung disease
- patient-reported outcome measures
- clinical trial endpoints
- trial design
- quality of life
- symptom burden
- treatment efficacy and tolerability
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Saketkoo, L. A., Scholand, M. B., Lammi, M. R., & Russell, A. (2020). Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials. Journal of Scleroderma and Related Disorders, 5(2_suppl), 48–60. https://doi.org/10.1177/2397198320904178
How many times has this paper been cited?
30 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Scleroderma and Related Disorders: sign in and open the PDF from this page.
Who wrote this paper?
Lesley Ann Saketkoo, Mary Beth Scholand, Matthew R. Lammi, Anne‐Marie Russell.
What is the DOI of this paper?
10.1177/2397198320904178, permanently at https://doi.org/10.1177/2397198320904178. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.